Gender as a biological variable: transcriptomic analysis of rectal mucosal immune cells among transgender people
性别作为生物变量:变性人直肠粘膜免疫细胞的转录组分析
基本信息
- 批准号:10376886
- 负责人:
- 金额:$ 19.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAndrogen AntagonistsB-LymphocytesBiologicalBiological AssayBiomedical ResearchBirthBloodCD22 geneCD28 geneCD80 geneCTLA4 geneCXCR3 geneCell physiologyCellsCharacteristicsChromosomesDataESR1 geneESR2 geneEnsureEnvironmentEstrogen ReceptorsEstrogensFemaleFoundationsFundingGenderGender IdentityGene ExpressionGenesGoalsGonadal Steroid HormonesHIVHIV InfectionsHIV vaccineIL2RG geneImmuneImmune systemImmunologicsImmunologyIndividualInnate Immune SystemInterventionInvestigationLightMediatingMicroRNAsModelingMucous MembraneNatural Killer CellsOutcomeParentsPathogenesisPathway interactionsPersonsPopulationPrevention strategyPublic HealthResearchResolutionSex ChromosomesSex DifferencesSiteTLR7 geneTNFSF5 geneTestosteroneTissuesUnited States National Institutes of HealthUntranslated RNAViral PathogenesisViral reservoirX Chromosomecis-femalecis-malecisgenderdesigndifferential expressiondysphoriaexperiencegender differencegender dysphoriahormone therapyimmunological diversityimmunoregulationinterestmalememory CD4 T lymphocytemicrobiomepre-exposure prophylaxisprogrammed cell death protein 1rectalsexsingle cell analysistranscription factortranscriptometranscriptomicstransgendertransgender mentransgender womentransmission processtreatment strategyvaccine responsexenoestrogen
项目摘要
Project summary
Transgender persons are individuals who were assigned a sex at birth, but experience dysphoria due to their
experienced gender not aligning with their assigned sex. One avenue of treatment for gender dysphoria is the
use of gender affirming hormone therapy to promote the physical characteristics of the desired sex. This is highly
relevant in light of the emerging binary (e.g. male/female) sex-specific differences in HIV vaccine responses,
pre-exposure prophylaxis efficacy, viral pathogenesis, and viral reservoir, that may be attributed, at least in part,
to sex hormones. Indeed, sex hormone-driven transcriptomic and functional diversity of immune cells within the
rectal mucosa (RM) of transgender individuals could have a profound impact on HIV prevention and treatment
strategies for theses populations. This is a strong argument for a critical need for basic, foundational research
into single-cell transcriptomics and functional assays of RM-residing immune cells, across the gender and sex
spectrum. In Aim 1, we will focus on defining the gender- and sex-specific features of adaptive immune cells
from cisgender men and women, as well as transgender men and women, via high-resolution, single-cell
transcriptomics. In Aim 2, we will define the gender- and sex-specific transcriptomic features of innate immune
cells, as well as quantifying gender and sex differences in NK cell function. A more complete understanding of
the spectrum of sex-hormone and sex-chromosome influence on the immune system will facilitate strategic HIV
prevention and treatment strategies appropriate for transgender individuals.
项目总结
变性人是出生时就被分配了性别,但由于他们的
经历的性别与他们分配的性别不一致。治疗性别焦虑症的一种方法是
使用性别肯定荷尔蒙疗法来促进理想性行为的身体特征。这是高度
与艾滋病毒疫苗反应中出现的二元(例如男性/女性)性别特定差异有关,
暴露前的预防效果、病毒致病机制和病毒库,这可能至少部分地归因于,
性激素。事实上,性激素驱动的免疫细胞内转录和功能的多样性
变性人的直肠粘膜(RM)可能对HIV的预防和治疗产生深远的影响
针对这些人群的战略。这是一个强有力的论据,证明了基础、基础研究的迫切需要
进入单细胞转录和居住在RM的免疫细胞的功能分析,跨越性别和性别
频谱。在目标1中,我们将重点定义适应性免疫细胞的性别和性别特征
来自顺性别男性和女性以及跨性别男性和女性,通过高分辨率的单细胞
转录学。在目标2中,我们将定义先天免疫的性别和性别特异性转录特征。
细胞,以及量化性别和性别差异的NK细胞功能。更全面地了解
性激素谱和性染色体对免疫系统的影响将促进战略性艾滋病毒
适合跨性别者的预防和治疗战略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Colleen F Kelley其他文献
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
PGDM1400LS 是一种 V2 特异性 HIV-1 广泛中和抗体,在美国无 HIV-1 人群中静脉或皮下输注的安全性、药代动力学和中和活性(HVTN 140/HPTN 101 A 部分):一项首次人体、1 期随机试验
- DOI:
10.1016/s2352-3018(25)00012-8 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:13.000
- 作者:
Kelly E Seaton;Carmen A Paez;Chenchen Yu;Shelly T Karuna;Theresa Gamble;Maurine D Miner;Jack Heptinstall;Lu Zhang;Fei Gao;Margaret Yacovone;Hans Spiegel;Julie B Dumond;Maija Anderson;Estelle Piwowar-Manning;Bonnie Dye;India Tindale;Lori Proulx-Burns;Meg Trahey;Simbarashe Takuva;Azwidihwi Takalani;Colleen F Kelley - 通讯作者:
Colleen F Kelley
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
开发用于评估体内结核病免疫力的人类卡介苗挑战模型的第一阶段开放标签剂量递增试验。
- DOI:
10.1093/infdis/jiad441 - 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Azra Blazevic;Rachel L Edwards;Mei Xia;C. Eickhoff;Fahreta Hamzabegovic;Krystal A. Meza;Huan Ning;Jan Tennant;Karla J Mosby;James C Ritchie;Tigisty Girmay;Lilin Lai;Michele McCullough;Allison Beck;Colleen F Kelley;Srilatha Edupuganti;Sarah Kabbani;Wendy Buchanan;M. Makhene;Delia Voronca;Sami R. Cherikh;Johannes B. Goll;N. Rouphael;Mark J. Mulligan;D. Hoft - 通讯作者:
D. Hoft
Colleen F Kelley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Colleen F Kelley', 18)}}的其他基金
Defining Sex-Specific Systemic and Gut Inflammatory Profiles in People Living with HIV
定义艾滋病毒感染者的性别特异性全身和肠道炎症特征
- 批准号:
10619980 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Gender as a biological variable: transcriptomic analysis of rectal mucosal immune cells among transgender people
性别作为生物变量:变性人直肠粘膜免疫细胞的转录组分析
- 批准号:
10258036 - 财政年份:2021
- 资助金额:
$ 19.56万 - 项目类别:
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs among Young Black MSM
避开 PrEP 的陷阱:防止年轻黑人 MSM 过早停止 PrEP 和性传播感染
- 批准号:
9927385 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs among Young Black MSM
避开 PrEP 的陷阱:防止年轻黑人 MSM 过早停止 PrEP 和性传播感染
- 批准号:
10133150 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs among Young Black MSM
避开 PrEP 的陷阱:防止年轻黑人 MSM 过早停止 PrEP 和性传播感染
- 批准号:
10652666 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs among Young Black MSM
避开 PrEP 的陷阱:防止年轻黑人 MSM 过早停止 PrEP 和性传播感染
- 批准号:
10399433 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Understanding the rectal mucosal effects of cross-sex hormone therapy among US and Thai transgender women
了解跨性别激素治疗对美国和泰国变性女性直肠粘膜的影响
- 批准号:
10672350 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Understanding the rectal mucosal effects of cross-sex hormone therapy among US and Thai transgender women
了解跨性别激素治疗对美国和泰国变性女性直肠粘膜的影响
- 批准号:
10227723 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Understanding the rectal mucosal effects of cross-sex hormone therapy among US and Thai transgender women
了解跨性别激素治疗对美国和泰国变性女性直肠粘膜的影响
- 批准号:
10447095 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
STI and Implications for HIV Transmission and Prevention
性传播感染以及对艾滋病毒传播和预防的影响
- 批准号:
9334534 - 财政年份:2017
- 资助金额:
$ 19.56万 - 项目类别:














{{item.name}}会员




